Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: A large multi-institutional study

Carmen Mir, Shahrokh F. Shariat, Theodorus H. Van Der Kwast, Raheela Ashfaq, Yair Lotan, Andrew Evans, Sean Skeldon, Sally Hanna, Rati Vajpeyi, Cynthia Kuk, Sultan Alkhateeb, Juan Morote, Bas W G Van Rhijn, Peter Bostrom, Jorge Yao, Hiroshi Miyamoto, Michael Jewett, Neil Fleshner, Ed Messing, Alexandre R. Zlotta

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

More men than women develop bladder cancer (BC) but reasons why are unclear. Recent findings have implicated androgens, androgen receptors (AR) and AR expression in BC. Previous studies showed that a significant loss of AR expression was associated with aggressive BC. However, these results have been gathered on limited series of patients. We analyzed the expression of AR in BC and its correlation with gender, grade, stage and clinical outcome on a large multi-institutional (Toronto/Dallas) cohort. In contrast to previous reports, our data do not suggest that loss of AR expression is gender-related nor associated with invasive BC. In fact, in this large cohort, we showed that AR positivity is actually uncommon in BC, that there are no differences in expression among high and low grade tumours and no statistically significant differences between muscle-invasive AR-positive and AR-negative cases in time to death, or time to recurrence. OBJECTIVE • To investigate androgen receptor (AR) expression in a large series of patients with bladder cancer (BC) because data on a limited number of patients showed that loss of AR expression was associated with invasive BC. PATIENTS AND METHODS • A total of 472 patients with urothelial bladder carcinoma (UBC) from two institutional centres (Toronto and Dallas) were analysed. Tissue microarrays comprising both non-muscle-invasive UBC (n= 167) and muscle-invasive UBC (n= 305) were accrued and immunohistochemical staining for AR was performed. • We used bright-field microscopy imaging coupled with advanced colour detection software to detect, classify and count stained cellular objects and manual scoring. • Results obtained in Dallas were blindly reviewed and validated in Toronto and samples randomly chosen were further analysed in Rochester, NY, USA. RESULTS • The AR were positively expressed in 61/472 (12.9%) bladder tumours. No statistically significant difference in AR expression between men and women was observed. • Only 9.0% of non-muscle-invasive BC expressed the AR compared with 15.1% of muscle-invasive tumours (P= 0.059). The highest percentage of AR positivity (28.9% of cases) was found in T2 tumours. • There was no statistically significant difference in death from BC, time to death, or time to recurrence between AR-positive and AR-negative cases. CONCLUSION • In contrast to previous reports, based on our large BC series, we did not observe a decrease in AR protein expression in bladder tumours with increased pathological stage. Our data do not suggest that loss of AR expression is gender-related nor is it associated with invasive BC.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalBJU International
Volume108
Issue number1
DOIs
StatePublished - Jul 2011

Fingerprint

Androgen Receptors
Urinary Bladder Neoplasms
Urinary Bladder
Carcinoma
Muscles
Recurrence
Neoplasms

Keywords

  • Androgen receptor
  • bladder cancer
  • immunohistochemistry
  • tissue microarrays

ASJC Scopus subject areas

  • Urology

Cite this

Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer : A large multi-institutional study. / Mir, Carmen; Shariat, Shahrokh F.; Van Der Kwast, Theodorus H.; Ashfaq, Raheela; Lotan, Yair; Evans, Andrew; Skeldon, Sean; Hanna, Sally; Vajpeyi, Rati; Kuk, Cynthia; Alkhateeb, Sultan; Morote, Juan; Van Rhijn, Bas W G; Bostrom, Peter; Yao, Jorge; Miyamoto, Hiroshi; Jewett, Michael; Fleshner, Neil; Messing, Ed; Zlotta, Alexandre R.

In: BJU International, Vol. 108, No. 1, 07.2011, p. 24-30.

Research output: Contribution to journalArticle

Mir, C, Shariat, SF, Van Der Kwast, TH, Ashfaq, R, Lotan, Y, Evans, A, Skeldon, S, Hanna, S, Vajpeyi, R, Kuk, C, Alkhateeb, S, Morote, J, Van Rhijn, BWG, Bostrom, P, Yao, J, Miyamoto, H, Jewett, M, Fleshner, N, Messing, E & Zlotta, AR 2011, 'Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: A large multi-institutional study', BJU International, vol. 108, no. 1, pp. 24-30. https://doi.org/10.1111/j.1464-410X.2010.09834.x
Mir, Carmen ; Shariat, Shahrokh F. ; Van Der Kwast, Theodorus H. ; Ashfaq, Raheela ; Lotan, Yair ; Evans, Andrew ; Skeldon, Sean ; Hanna, Sally ; Vajpeyi, Rati ; Kuk, Cynthia ; Alkhateeb, Sultan ; Morote, Juan ; Van Rhijn, Bas W G ; Bostrom, Peter ; Yao, Jorge ; Miyamoto, Hiroshi ; Jewett, Michael ; Fleshner, Neil ; Messing, Ed ; Zlotta, Alexandre R. / Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer : A large multi-institutional study. In: BJU International. 2011 ; Vol. 108, No. 1. pp. 24-30.
@article{6ee988948d3a461385dc16264d5fe7e7,
title = "Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: A large multi-institutional study",
abstract = "More men than women develop bladder cancer (BC) but reasons why are unclear. Recent findings have implicated androgens, androgen receptors (AR) and AR expression in BC. Previous studies showed that a significant loss of AR expression was associated with aggressive BC. However, these results have been gathered on limited series of patients. We analyzed the expression of AR in BC and its correlation with gender, grade, stage and clinical outcome on a large multi-institutional (Toronto/Dallas) cohort. In contrast to previous reports, our data do not suggest that loss of AR expression is gender-related nor associated with invasive BC. In fact, in this large cohort, we showed that AR positivity is actually uncommon in BC, that there are no differences in expression among high and low grade tumours and no statistically significant differences between muscle-invasive AR-positive and AR-negative cases in time to death, or time to recurrence. OBJECTIVE • To investigate androgen receptor (AR) expression in a large series of patients with bladder cancer (BC) because data on a limited number of patients showed that loss of AR expression was associated with invasive BC. PATIENTS AND METHODS • A total of 472 patients with urothelial bladder carcinoma (UBC) from two institutional centres (Toronto and Dallas) were analysed. Tissue microarrays comprising both non-muscle-invasive UBC (n= 167) and muscle-invasive UBC (n= 305) were accrued and immunohistochemical staining for AR was performed. • We used bright-field microscopy imaging coupled with advanced colour detection software to detect, classify and count stained cellular objects and manual scoring. • Results obtained in Dallas were blindly reviewed and validated in Toronto and samples randomly chosen were further analysed in Rochester, NY, USA. RESULTS • The AR were positively expressed in 61/472 (12.9{\%}) bladder tumours. No statistically significant difference in AR expression between men and women was observed. • Only 9.0{\%} of non-muscle-invasive BC expressed the AR compared with 15.1{\%} of muscle-invasive tumours (P= 0.059). The highest percentage of AR positivity (28.9{\%} of cases) was found in T2 tumours. • There was no statistically significant difference in death from BC, time to death, or time to recurrence between AR-positive and AR-negative cases. CONCLUSION • In contrast to previous reports, based on our large BC series, we did not observe a decrease in AR protein expression in bladder tumours with increased pathological stage. Our data do not suggest that loss of AR expression is gender-related nor is it associated with invasive BC.",
keywords = "Androgen receptor, bladder cancer, immunohistochemistry, tissue microarrays",
author = "Carmen Mir and Shariat, {Shahrokh F.} and {Van Der Kwast}, {Theodorus H.} and Raheela Ashfaq and Yair Lotan and Andrew Evans and Sean Skeldon and Sally Hanna and Rati Vajpeyi and Cynthia Kuk and Sultan Alkhateeb and Juan Morote and {Van Rhijn}, {Bas W G} and Peter Bostrom and Jorge Yao and Hiroshi Miyamoto and Michael Jewett and Neil Fleshner and Ed Messing and Zlotta, {Alexandre R.}",
year = "2011",
month = "7",
doi = "10.1111/j.1464-410X.2010.09834.x",
language = "English (US)",
volume = "108",
pages = "24--30",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer

T2 - A large multi-institutional study

AU - Mir, Carmen

AU - Shariat, Shahrokh F.

AU - Van Der Kwast, Theodorus H.

AU - Ashfaq, Raheela

AU - Lotan, Yair

AU - Evans, Andrew

AU - Skeldon, Sean

AU - Hanna, Sally

AU - Vajpeyi, Rati

AU - Kuk, Cynthia

AU - Alkhateeb, Sultan

AU - Morote, Juan

AU - Van Rhijn, Bas W G

AU - Bostrom, Peter

AU - Yao, Jorge

AU - Miyamoto, Hiroshi

AU - Jewett, Michael

AU - Fleshner, Neil

AU - Messing, Ed

AU - Zlotta, Alexandre R.

PY - 2011/7

Y1 - 2011/7

N2 - More men than women develop bladder cancer (BC) but reasons why are unclear. Recent findings have implicated androgens, androgen receptors (AR) and AR expression in BC. Previous studies showed that a significant loss of AR expression was associated with aggressive BC. However, these results have been gathered on limited series of patients. We analyzed the expression of AR in BC and its correlation with gender, grade, stage and clinical outcome on a large multi-institutional (Toronto/Dallas) cohort. In contrast to previous reports, our data do not suggest that loss of AR expression is gender-related nor associated with invasive BC. In fact, in this large cohort, we showed that AR positivity is actually uncommon in BC, that there are no differences in expression among high and low grade tumours and no statistically significant differences between muscle-invasive AR-positive and AR-negative cases in time to death, or time to recurrence. OBJECTIVE • To investigate androgen receptor (AR) expression in a large series of patients with bladder cancer (BC) because data on a limited number of patients showed that loss of AR expression was associated with invasive BC. PATIENTS AND METHODS • A total of 472 patients with urothelial bladder carcinoma (UBC) from two institutional centres (Toronto and Dallas) were analysed. Tissue microarrays comprising both non-muscle-invasive UBC (n= 167) and muscle-invasive UBC (n= 305) were accrued and immunohistochemical staining for AR was performed. • We used bright-field microscopy imaging coupled with advanced colour detection software to detect, classify and count stained cellular objects and manual scoring. • Results obtained in Dallas were blindly reviewed and validated in Toronto and samples randomly chosen were further analysed in Rochester, NY, USA. RESULTS • The AR were positively expressed in 61/472 (12.9%) bladder tumours. No statistically significant difference in AR expression between men and women was observed. • Only 9.0% of non-muscle-invasive BC expressed the AR compared with 15.1% of muscle-invasive tumours (P= 0.059). The highest percentage of AR positivity (28.9% of cases) was found in T2 tumours. • There was no statistically significant difference in death from BC, time to death, or time to recurrence between AR-positive and AR-negative cases. CONCLUSION • In contrast to previous reports, based on our large BC series, we did not observe a decrease in AR protein expression in bladder tumours with increased pathological stage. Our data do not suggest that loss of AR expression is gender-related nor is it associated with invasive BC.

AB - More men than women develop bladder cancer (BC) but reasons why are unclear. Recent findings have implicated androgens, androgen receptors (AR) and AR expression in BC. Previous studies showed that a significant loss of AR expression was associated with aggressive BC. However, these results have been gathered on limited series of patients. We analyzed the expression of AR in BC and its correlation with gender, grade, stage and clinical outcome on a large multi-institutional (Toronto/Dallas) cohort. In contrast to previous reports, our data do not suggest that loss of AR expression is gender-related nor associated with invasive BC. In fact, in this large cohort, we showed that AR positivity is actually uncommon in BC, that there are no differences in expression among high and low grade tumours and no statistically significant differences between muscle-invasive AR-positive and AR-negative cases in time to death, or time to recurrence. OBJECTIVE • To investigate androgen receptor (AR) expression in a large series of patients with bladder cancer (BC) because data on a limited number of patients showed that loss of AR expression was associated with invasive BC. PATIENTS AND METHODS • A total of 472 patients with urothelial bladder carcinoma (UBC) from two institutional centres (Toronto and Dallas) were analysed. Tissue microarrays comprising both non-muscle-invasive UBC (n= 167) and muscle-invasive UBC (n= 305) were accrued and immunohistochemical staining for AR was performed. • We used bright-field microscopy imaging coupled with advanced colour detection software to detect, classify and count stained cellular objects and manual scoring. • Results obtained in Dallas were blindly reviewed and validated in Toronto and samples randomly chosen were further analysed in Rochester, NY, USA. RESULTS • The AR were positively expressed in 61/472 (12.9%) bladder tumours. No statistically significant difference in AR expression between men and women was observed. • Only 9.0% of non-muscle-invasive BC expressed the AR compared with 15.1% of muscle-invasive tumours (P= 0.059). The highest percentage of AR positivity (28.9% of cases) was found in T2 tumours. • There was no statistically significant difference in death from BC, time to death, or time to recurrence between AR-positive and AR-negative cases. CONCLUSION • In contrast to previous reports, based on our large BC series, we did not observe a decrease in AR protein expression in bladder tumours with increased pathological stage. Our data do not suggest that loss of AR expression is gender-related nor is it associated with invasive BC.

KW - Androgen receptor

KW - bladder cancer

KW - immunohistochemistry

KW - tissue microarrays

UR - http://www.scopus.com/inward/record.url?scp=79959286044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959286044&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2010.09834.x

DO - 10.1111/j.1464-410X.2010.09834.x

M3 - Article

C2 - 21070579

AN - SCOPUS:79959286044

VL - 108

SP - 24

EP - 30

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -